Target intelligence / Profile preview

Ataxin-1 messenger RNA (ATXN1 mRNA)

Target
ATXN1 mRNA
Molecular classification
Other (as an mRNA/therapeutic nucleic acid target), Disease-associated messenger RNA
01

Overview

Ataxin-1 mRNA is the messenger RNA produced from the *ATXN1* gene, which encodes the ataxin-1 protein. The ataxin-1 protein is a polyglutamine-containing nuclear protein involved in transcriptional repression, chromatin binding, and RNA processing, and is particularly implicated in neuronal function. Expanded CAG repeats in the mRNA lead to a longer polyglutamine tract in the translated protein and cause spinocerebellar ataxia type 1 (SCA1), a progressive neurodegenerative disorder characterized by loss of cerebellar Purkinje neurons[7][9]. Ataxin-1 is also implicated in immune function and cancer. The mRNA itself is of therapeutic interest primarily for gene-silencing approaches aiming to lower mutant protein expression in SCA1 and related disorders[7][9].

Other names
ATXN1 mRNASpinocerebellar ataxia type 1 mRNASCA1 mRNAAtx1 mRNA
02

Mechanism of action

Antisense oligonucleotide binding followed by RNase H-mediated degradation of ataxin-1 mRNA or translation inhibition. RNA interference (siRNA or shRNA targeting ataxin-1 mRNA). Modulation of splicing to skip mutant exons (hypothetical/mechanistic).

03

Biological functions

Encodes the ataxin-1 protein, which is involved in transcriptional regulation (as the ataxin-1 protein acts as a transcriptional repressor when translated)Neurological function (via downstream protein function)RNA processing (as with many mRNAs, it is subject to nuclear export, translation, and degradation)
04

Disease associations

Neurodegenerative disease (spinocerebellar ataxia type 1)Multiple sclerosis risk locus (recent human genetics studies)Cancer (loss-of-function implication)Alzheimer’s disease pathogenesis (loss-of-function implication)
05

Safety considerations

Off-target effects of mRNA-targeted therapiesPotential for neurotoxicity if normal ataxin-1 function is excessively reducedImmune activation by nucleic acid-based drugs
06

Interacting drugs

Antisense oligonucleotides

2 more in the full profile.

07

Biomarkers

Ataxin-1 mRNA expression levels (used in research settings or as a pharmacodynamic biomarker if mRNA-targeted therapy is being developed)Expanded CAG repeat length in the ataxin-1 gene (for diagnosis/risk stratification of SCA1)

Beyond the preview

Go deeper on Ataxin-1 messenger RNA (ATXN1 mRNA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ataxin-1 messenger RNA (ATXN1 mRNA).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call